On this first World Hepatitis Testing Week, World Hepatitis Alliance (WHA) and Abbott have come together in recognition of the need for innovative new approaches and partnerships to tackle the challenges facing us. Through Abbott’s support for World Hepatitis Testing Week, WHA are able to deliver the global campaign, providing support and resources for advocates and organisations around the world to drive testing in their communities. Abbott’s support has also enabled WHA to deliver a series of activations that shine a light on the challenges and inequity of lack of access to testing for pregnant women, and the devastating impact seen in the continued transmission of hepatitis B from mother-to-child.

This is an area where Abbott and WHA align in our belief that we can have a significant impact not just in increasing hepatitis B testing rates but on the lives of women and their families. The elimination of vertical transmission of hepatitis B is possible and can be integrated into existing antenatal services and efforts to eliminate the transmission of HIV and syphilis from mother to child.

To help drive this, in the run up to and during this World Hepatitis Testing Week, with Abbott’s support, World Hepatitis Alliance will be conducting the below activities.

Educational posters

The NOhep Mums posters raise awareness of and increase education around testing pregnant women for hepatitis B. They reflect the new WHO Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection and are designed to ensure that pregnant women and their families better understand the testing pathway and are better able to advocate for access to this. A complimentary poster for healthcare professionals ensures they have the latest guidelines at their fingertips.

Posters now available.

World Hepatitis Testing Week Posters

We have also created some posters specific to World Hepatitis Testing Week that highlight the importance of testing in antenatal settings. 

Hepatitis Testing Week Campaign Video – Copy
Zoom Background – Copy
Language:
Abbott 6
Language:
Abbott 5
Language:
Abbott 4
Language:
Abbott 3
Language:
Abbott 2
Language:
Abbott 1
Language:

Webinar

Our NOhep Mums: scaling up testing in antenatal settings to support the elimination of hepatitis B webinar took place on Tuesday 5 November at 1 p.m. GMT for healthcare professionals, policymakers and community members.

Ending vertical transmission of hepatitis B is key to achieving hepatitis elimination. 254 million people are living with hepatitis B worldwide, with the majority of people infected as infants through mother-to-child transmission. This is largely being driven due to a lack of testing, with only 13% of people living with hepatitis B having been diagnosed. Ahead of World Hepatitis Testing Week, this webinar explored the importance of hepatitis B testing in antenatal settings. It looked at the critical role testing can play in not only preventing mother-to-child transmission but also unlocking wider diagnosis opportunities for their family members and so driving elimination efforts.

Community testing workshops

Hepatitis elimination will not be reached unless we find the missing millions and community groups are expertly placed to help deliver this. To build the capacity of WHA members and other civil society organisations around testing two workshops were delivered the week before World Hepatitis Testing Week. The workshops built upon the understanding diagnostics modules of the WHA Community Impact Programme (CIP) e-learning and a newly launched community testing brief. Held in both English and Spanish, the workshops covered the importance of testing, different types of tests, and testing in practice.

English Workshop

Date: 14 November from 09:00 to 10:30 GMT

Hepatitis testing and the path to elimination: Practical advice for communities

Spanish Workshop

Date: 14 November from 15:00 to 16:30 GMT

Pruebas de hepatitis y el camino hacia la eliminación: consejos prácticos para las comunidades

Europe

  • An estimated 9.7 million people live with hepatitis B. Only 23% have been diagnosed, and just 4.2% are receiving the treatment they would need.
  • An estimated 5.6 million people live with hepatitis C. Only 45% have been diagnosed, and just 23% are receiving the treatment they would need.